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Paclitaxel-induced neuropathic pain is a major dose-limiting side eﬀect of paclitaxel therapy. -is study characterises a variety of
rat behavioural responses induced by intermittent administration of clinically formulated paclitaxel. 2mg/kg paclitaxel or
equivalent vehicle was administered intraperitoneally on days 0, 2, 4, and 6 to adult male Sprague-Dawley rats. Evoked pain-like
behaviours were assessed with von Frey ﬁlaments, acetone, or radiant heat application to plantar hind paws to ascertain me-
chanical, cold, or heat sensitivity, respectively. Motor coordination was evaluated using an accelerating RotaRod apparatus.
Ongoing pain-like behaviour was assessed via spontaneous burrowing and nocturnal wheel running. Mechanical and cold
hypersensitivity developed after a delayed onset, peaked approximately on day 28, and persisted for several months. Heat
sensitivity and motor coordination were unaltered in paclitaxel-treated rats. Spontaneous burrowing behaviour and nocturnal
wheel running were signiﬁcantly impaired on day 28, but not on day 7, indicating ongoing pain-like behaviour, rather than acute
drug toxicity. -is study comprehensively characterises a rat model of paclitaxel-induced peripheral neuropathy, providing the
ﬁrst evidence for ongoing pain-like behaviour, which occurs in parallel with maximal mechanical/cold hypersensitivity. We hope
that this new data improve the face validity of rat models to better reﬂect patient-reported pain symptoms, aiding translation of
new treatments to the clinic.
1. Introduction
Paclitaxel is a highly eﬀective anticancer agent with the major
dose-limiting side eﬀect of neuropathic pain. Patients describe
an array of sensory symptoms in the hands and/or feet in-
cluding numbness, tingling, ongoing pain, and mechanical
and cold hypersensitivity. -ese symptoms signiﬁcantly im-
pact the quality of life, for example, pain on walking and
inability to remove items from a fridge/freezer [1, 2]. Deep
tendon reﬂexes and temperature and vibration perceptionmay
also be lost in severe cases. Mild weakness has been reported in
some patients receiving very high doses of paclitaxel. However,
paclitaxel-induced neuropathy usually presents as a pre-
dominantly sensory neuropathy, increasing in severity with
higher cumulative doses, which persists for months to years
after termination of treatment [3–7]. Meta-analysis of clinical
studies indicates that some degree of neuropathy is reported in
44%–98% of paclitaxel-treated patients [8]. Alleviation or
prevention of chemotherapy-induced neuropathic pain is
a challenging clinical issue as many analgesics are ineﬀective
(reviewed in [9, 10]), and only duloxetine has a moderate
recommendation [9, 11].
Given the lack of treatment options for chemotherapy-
induced neuropathic pain, it is important to understand
the underlying mechanisms of this disorder. Using rat
models can provide a means to investigate paclitaxel-
induced neuropathic pain, thus enabling mechanistic
studies that would be infeasible/unethical in humans.
Several rodent models have been developed utilising dif-
ferent dosing regimens of paclitaxel (reviewed in [12]).
-ese studies report the assessment of evoked pain-like
behaviours using mechanical and thermal stimuli applied
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to the hind paw. However, the complete time course and
resolution of these evoked pain-like behaviours are
underreported.
Accurate modelling of ongoing pain in rodent models is
challenging as patient reporting relies on verbal report. To
better model patient symptoms, current pain-like behav-
ioural techniques could be improved with the addition of
ethological testing such as burrowing and spontaneous
wheel-running assays. For rodents, burrowing is a natural
behaviour that can be disrupted if normal physiology is
altered, for example, by anxiety [13]. Previous studies have
shown that burrowing behaviour is impaired in in-
ﬂammatory and neuropathic pain models and can be re-
versed by analgesics at clinically relevant doses [14–16].
Spontaneous wheel running has also been shown to be an
elective, natural behaviour [17]. Spontaneous wheel running
is also impaired in inﬂammatory pain models [18, 19] and
can be ameliorated by NSAIDs at doses devoid of anti-
allodynic eﬀects [18]. -ese studies show that ethological
testing can measure ongoing pain-like behaviours in rat
models of chronic pain.
Here, we have used a rat model of paclitaxel-induced
painful neuropathy evoked by intermittent systemic ad-
ministration of low doses of clinically formulated paclitaxel
to replicate treatment cycles. -is paclitaxel dosing regimen
has been frequently used by our lab [20–22] and other
groups. However, our aims with this study were to more
fully characterise the behavioural phenotype in this model
without variation in the rodent strain, experimenter, drug
formulation, or dosage administered, to describe the com-
plete time course of evoked pain-like behaviours and motor
coordination in this low-dose paclitaxel model, and to assess
two ethologically relevant behavioural tests: spontaneous
burrowing and nocturnal wheel running. -erefore, we
report, for the ﬁrst time, the evoked and ongoing pain-like
behaviours associated with paclitaxel-induced neuropathy in
rats.
2. Materials and Methods
2.1. Animals. Adult male Sprague-Dawley rats (175–200 g;
Harlan/Envigo) were housed in groups of three or four in
a temperature-controlled room with a 12-hour light/dark
cycle. A phased “sunset” and “sunrise” lighting period over
∼30min preceded complete dark/light periods. By 7 am, the
room was fully illuminated. All cages contained sawdust
bedding with environmental enrichment materials, and
food/water was freely available. All procedures were con-
ducted in strict accordance with the UK Animals (Scientiﬁc
Procedures) Act 1986 and IASP ethical guidelines [23].
Protocols used were approved by the Ethics Review Panel of
King’s College London and conducted under the UK Home
Oﬃce project licenses 70/6673 and 70/8015. Unless other-
wise stated below, the rats were habituated to the testing
environment for 20–30 minutes on three separate occasions
before baseline testing. -e rats were alert, not grooming or
sleeping, during assessment of all evoked pain-like behav-
iours. Unless otherwise stated, behavioural assessment oc-
curred between 8 and 11 am. Separate cohorts of rats were
used for the assessment of the diﬀerent behavioural tests to
avoid the impact of diﬀerent hind paw stimuli on other
behavioural assessments. -e only exception to this was in
one cohort of rats where cold hypersensitivity was assessed
in the morning and motor coordination in the afternoon. A
total of 109 rats were used in these studies. An equally sized
concurrent vehicle-treated group was tested in parallel with
the paclitaxel-treated rats in all experiments. No rats were
excluded from these studies due to weight loss or their
response to behavioural testing.
2.2. Administration of Paclitaxel. Clinically formulated
paclitaxel solution for infusion (6mg/ml; CP Pharmaceu-
ticals UK or Actavis UK) was diluted with 0.9% sterile saline
(Fresenius Kabi, UK) to achieve a 2mg/ml solution for
injection. To replicate the clinical formulation, a vehicle
stock solution was made using 1 :1 solution of Cremophor
EL (Sigma, UK) and ethanol. When using paclitaxel from
Actavis, the vehicle stock was supplemented with 2mg/mL
sodium citrate (Sigma, UK). Prior to administration, one
part of vehicle stock solution was diluted with two parts of
0.9% sterile saline. -e rats were dosed with 2mg/kg pac-
litaxel or equivalent volume of vehicle solution in-
traperitoneally on four alternate days (0, 2, 4, and 6).
Animals were dosed according to their weight (1ml/kg) and
were immediately returned to their home cages. All
paclitaxel/vehicle injections were administered in the early
afternoon 1–3 pm. Both paclitaxel and vehicle solutions are
clear solutions with the same viscosity, which enables
blinding procedures (see below).
2.3. Mechanical Hypersensitivity. Mechanical hypersensi-
tivity was assessed using von Frey ﬁlaments (Touch-Test™
Sensory Evaluators, Linton Instrumentation, UK) as pre-
viously described [20–22, 24]. -e rats were placed in ele-
vated, clear Perspex boxes (15 cm× 16 cm× 21 cm) with
a wire-rung ﬂoor and allowed to acclimatise.When still alert,
and with all four paws in contact with the ﬂoor, von Frey
ﬁlaments (4 g, 8 g, and 15 g) were applied to the hind paws in
the ascending order of force. Each von Frey ﬁlament was
applied to ﬁve discrete points on the midplantar region of
each hind paw and held in place for ﬁve seconds, and the
number of withdrawals was recorded. All rats were tested
using one von Frey ﬁlament on one hind paw before be-
ginning to test the other hind paw with the same bending
force ﬁlament. -e scores of both hind paws were added
together to give a withdrawal score out of ten for each von
Frey ﬁlament. After habituation, three baseline measure-
ments were taken on separate days prior to administration of
paclitaxel/vehicle. von Frey withdrawal responses were then
typically assessed on days 7, 14, 21, 28, 35, 49, 62, 77, 90, 104,
119, 132, 148, 166, and 174 to determine the time course of
paclitaxel-induced mechanical hypersensitivity. After day
174, the rats were tested every 7–10 days until resolution of
mechanical hypersensitivity. Resolution of mechanical hy-
persensitivity was variable between rats and was considered
resolved when withdrawal responses had returned to
baseline response levels on two separate occasions (spaced
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approx. 7 days apart). Data are combined from experiments
with ﬁve small cohorts of rats (n � 3–6 per treatment group),
which were performed over a 2.5-year period. Over this 2.5-
year period, there were unexpected changes in the colony of
Sprague-Dawley rats and the brand of paclitaxel available
from our regular suppliers. -erefore, to ensure consistency,
additional cohorts were run by the same experimenter
(LAG). Importantly, an equally sized concurrent vehicle-
treated group was tested in parallel within each cohort at
each time point. -ere is variability in n at diﬀerent time
points because it was not possible to test each cohort on all
the same days. Sample sizes for each treatment group at each
time point were as follows: n � 21 at baseline and on days 7,
21, 28, 77, 90, 104, 132, 148, and 166; n � 18 on days 62 and
119; and n � 15 on days 14 and 35. As this combined data set
is not uniform, it does not meet the requirements for a re-
peated measures ANOVA. -erefore, unpaired t-tests were
used, and the Bonferroni correction was applied to account
for repeated testing (see Section 2.10).
2.4. Cold Hypersensitivity. Cold hypersensitivity was
assessed using acetone as previously described [24, 25]. -e
testing apparatus for cold hypersensitivity assessment was
the same as used for mechanical hypersensitivity. 50 µl of
acetone was applied to the plantar surface of each hind paw
using a P200 pipette and a stopwatch started. Care was taken
to avoid the spread of acetone onto any of the animals’ fur
(this alters or masks the hind paw response as they will
attend to the wetted fur only). Responses were graded as
follows: 0� no response; 1� single withdrawal (lifting,
ﬂicking, or stamping the paw); 2�multiple or prolonged
withdrawals; and 3� paw withdrawal and licked on the
plantar surface. Responses were scored for 20 seconds fol-
lowing acetone application. If the rat did respond within this
period, the rat’s response was assessed for an additional 20
seconds. Previous extensive observations showed that if a rat
had not responded within the ﬁrst 20 seconds following
acetone application, then no response would be observed in
any additional time. -e additional 20 seconds following an
initial response allowed complete observation of the inter-
rupted behaviour evoked by plantar hind paw acetone ap-
plication. Responses were assessed for the left hind paw of
each rat, followed by the right hind paw, and repeated three
times. -e scores from each hind paw response were added
together to give a score out of a maximum of 18 points (six
acetone applications multiplied by 3 points). Hind paw
testing was nonconsecutive, with each rat tested on one hind
paw before returning to test the ﬁrst rat’s other hind paw. A
minimum period of 10 minutes had passed before the next
acetone application was applied to the same hind paw. Data
are combined from experiments with two cohorts of rats
(n � 6 per treatment group), which were performed over
a 2-year period. Over this time, there were unexpected
changes in the colony of Sprague-Dawley rats and the brand
of paclitaxel available from our regular suppliers. -erefore,
to ensure consistency, two cohorts were run by the same
experimenter (LAG), resulting in a combined data set with
n � 12 per treatment group.
2.5. Heat Hypersensitivity. Heat hypersensitivity was eval-
uated using a radiant heat source [26]. -e testing apparatus
consisted of six clear Perspex boxes (dimensions
22 cm× 17 cm× 14 cm) with a glass ﬂoor. -e plantar heel
surface of each hind paw was stimulated with an infrared
beam (Ugo Basile, Italy), which cut oﬀ when the rat with-
drew its paw. -e latency from initiation of stimulation to
paw withdrawal was then recorded. Responses were assessed
for the left hind paw of each rat, followed by the right hind
paw, and repeated three times. Approximately eight minutes
passed between stimulating the same hind paw. Latencies
were added together to give the mean of six measurements.
-e infrared intensity was maintained at 149–162mW/cm3
asmeasured using the Heat-Flux Radiometer throughout the
time course investigated (Ugo Basile, Italy) (n � 6 per
treatment group).
2.6. Motor Coordination. Motor coordination was assessed
using an accelerating RotaRod apparatus (Ugo Basile, Italy)
[27]. -e rats were habituated to the testing apparatus by
placing their cages next to the apparatus with the motor
switched on for ∼10 minutes on two occasions.-e rats were
placed on the apparatus, one to each lane, with an initial
speed of 4 rpm. Once the rats were in position, the accel-
eration program gradually increased the speed of rotation
from 4 to 40 rpm over ﬁve minutes (300 seconds). -e la-
tency time in seconds to fall onto the sensor platform was
recorded. Two to four training sessions were given to ensure
that all rats could stay on the apparatus for a minimum of
180 seconds, followed by one baseline measurement before
commencing paclitaxel or vehicle treatment (n � 6 per
treatment group).
2.7. Burrowing Behaviour. Burrowing behaviour was in-
vestigated using custom-made burrowing tubes (with sup-
plies purchased from B&Q plc, UK) in a protocol based on
previously published studies [13, 15, 28, 29]. Plastic bur-
rowing tubes were 32 cm in length and 10 cm in diameter
and had one end sealed. -e open end was raised by ap-
proximately 6 cm. Test cages contained an empty burrowing
tube on sawdust bedding, with food/water ad libitum. Test
cages were kept within the room where the rats were nor-
mally housed. -e rats were housed in pairs and habituated
to the test cages for 24 hours prior to the ﬁrst training
session. Training sessions consisted of the cage mates
moving to a test cage (they had been habituated to) with the
burrowing tube ﬁlled with 2500 g of 5mm pea shingle
(Porton Garden, Aquatics & Pets Centre, UK). Animals were
trained in pairs for 2 hours, from 4 to 6 pm, after which they
were returned to their original home cage with sawdust and
environmental enrichmentmaterials, without the burrowing
tube. -e following day, the process was repeated for the
second training session. If any pairs of rats did not burrow in
the ﬁrst training session, the pairings were swapped with the
rats that did show burrowing activity. For baseline testing,
which occurred 24 hours following the second training
session, the rats were placed individually in cages containing
burrowing tubes ﬁlled with 2500 g of pea shingle at 4 pm.-e
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rats were observed to record the time taken until burrowing
was initiated (latency to burrow). After two hours, the amount
of gravel left in the tubewasmeasured to determine the amount
of gravel burrowed. All animals burrowed more than 500 g at
baseline, a previously described minimum requirement for
study inclusion [15, 30]. In between subsequent burrowing
sessions, the rats were housedwith their original respective cage
mate. -e rats were assessed again on days 7 and 28 for the
latency time to burrow and the amount of gravel burrowed.
Burrowing sessions always took place at the same time each day
(4–6pm). -e weight of gravel dislodged at baseline was used
to group match the animals prior to drug administration,
ensuring similar baseline burrowing behaviour between
treatment groups. No animals were excluded from the analysis
(n � 6 per treatment group).
2.8. Spontaneous Wheel Running. Spontaneous wheel-
running activity was recorded using Activity Wheels
designed for rats (model BIO-ACTIVW-R; Bioseb, Bou-
logne, France). Software enabled recording of activity within
a cage similar to the rat’s home cage with dimensions of
48× 31.5× 47 cm and wheel dimensions of 34 cm height and
7 cm width. Animals had free access to food, water, and the
wheel at all times. Activity wheel cages contained sawdust
bedding only (no environmental enrichment materials) and
were kept within the room where the rats were normally
housed. Animals were individually housed in activity wheel
cages during recording periods, after which they were
returned to their home cage with the same cage mates.
Animals were habituated to the activity wheel cage for one
hour during the day (10-11 am), prior to overnight re-
cordings. For overnight recordings, animals were placed in
their activity wheel cage at 6 pm and were returned to their
home cage at ∼9 am the following day. Previous studies have
shown that the majority of spontaneous wheel running
occurs during the night in rats [31], so the period was the
focus in our study. Wheel-running data were split into
the dusk phase (6-7 pm) and night phase (7.10 pm–6.20 am).
-e wheels were connected to a laptop with software that
automatically recorded several parameters throughout the
recording period: time spent on the wheel (active time), total
distance travelled, maximal acceleration, the number of
times the rat entered the wheel (access count), and mean
speed. Prior to paclitaxel/vehicle administration, the rats
were grouped based on matching-pairing of overnight total
distances recorded at the baseline time point. Animals were
placed in their activity wheel cage again on days 7, 28, and 35
for one hour during the light cycle to habituate and then
from 6 pm to 9 am the following day. Animals were exposed
to the same wheel and cage throughout all experiments. Due
to limited equipment, two diﬀerent cohorts of animals
consisting of n � 5 per treatment group were tested. Un-
expectedly, during the ﬁrst experiment, one animal receiving
paclitaxel died during the injection period. We suspect that
this was due to a subclinical infection in this animal, which
was then exacerbated by paclitaxel administration. -is is
a highly unusual event, which has not occurred previously in
our lab. As this experiment resulted in n � 4 for the
paclitaxel group and n � 5 for the vehicle group, too low for
robust statistical analysis, we repeated the experiment again.
-erefore, the combined data set from both blinded ex-
periments was n � 9 for the paclitaxel group and n � 10 for
the vehicle group. No animals were excluded from data
analysis based on their wheel-running behaviour. Baseline
data were variable between animals, and this was taken into
account in the statistical analysis by using ANCOVA as
opposed to ANOVA.
2.9. Blinding and Randomisation. All behavioural testing
was performed by a single experimenter, under blind
conditions, to avoid unconscious bias. Animals were des-
ignated to experimental groups based on their respective
baseline responses to each behavioural test. Behavioural
extraneous variables were minimised by testing concurrent
vehicle-treated groups of equal size throughout all experi-
ments. Drug treatments were randomised within a given
cohort of animals. Prior to drug/vehicle administration,
injection vials were anonymised by a third party. At the end
of the experiment, the identity of the treatment each rat
received was revealed for data analysis.
2.10. Statistical Analysis. All statistical analyses were carried
out using GraphPad Prism 6.07 or IBM SPSS Statistics 23.
Typically, the statistical signiﬁcance was accepted at p≤ 0.05,
with no further distinctionmade for p< 0.01.Weight gain in
paclitaxel- versus vehicle-treated rats was assessed using
two-way repeated measures analysis of variance (ANOVA).
Mechanical hypersensitivity in paclitaxel-treated rats com-
pared to concurrent vehicle-treated rats was analysed using
two-tailed unpaired t-tests with Bonferroni correction for
multiple comparisons. For example, on day 35 (the ﬁfth
repeated test from baseline), the signiﬁcance was accepted if
p< 0.01 (0.05 divided by 5); on day 119 (the eleventh re-
peated test from baseline), the signiﬁcance was accepted if
p< 0.0045 (0.05 divided by 11). To assess cold hypersensi-
tivity, responses are categorised, and therefore, the non-
parametric Friedman test (nonparametric equivalent to RM
ANOVA) with Dunn’s post hoc test was utilised, comparing
the baseline scores in each group. -e eﬀect of paclitaxel on
heat hypersensitivity and motor coordination was analysed
using two-way repeated measures ANOVA. For burrowing
behaviour, the gravel displaced and latency to initiate
burrowing were analysed using one-way repeated measures
ANOVA with Dunnett’s post hoc test comparing the
baseline measurements. -e eﬀect of paclitaxel adminis-
tration on spontaneous wheel-running behaviour was
analysed using two-way repeated measures ANCOVA
(analysis of covariance), using baseline values as the co-
variate. Pairwise analysis was also conducted in SPSS, ap-
plying Bonferroni adjustment. No animals were excluded
from any analyses conducted.
3. Results
All animals were healthy throughout the studies, with-
out evidence of alopecia or diarrhoea. Paclitaxel- and
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vehicle-treated rats gained weight similarly throughout
the studies, with no signicant di
erence between pac-
litaxel- and vehicle-treated rats at any time point in-
vestigated (Figure 1; n  18 per group).
Figure 2 shows that administration of low-dose pacli-
taxel induced a robust and long-lasting mechanical hyper-
sensitivity. Following four systemic injections of 2mg/kg
paclitaxel on days 0, 2, 4, and 6, there was a short delay until
the onset of mechanical hypersensitivity. On day 14, sta-
tistically signicant mechanical hypersensitivity started to
emerge, which peaked by day 28. Paclitaxel-induced me-
chanical hypersensitivity was signicantly persistent with
a long-lasting plateau, apparent for four months following
paclitaxel administration (Figure 2; n  15–21; p< 0.05,
two-tailed unpaired t-tests with Bonferroni correction). e
resolution of paclitaxel-induced mechanical hypersensitivity
was variable between di
erent rats, resolving between days
174 and 219 (Figure 2). Mechanical hypersensitivity was
considered to have resolved in an individual rat when
withdrawal responses had returned to that rat’s baseline
responses before paclitaxel administration on two separate
occasions (which were spaced approx. one week apart).
Paclitaxel administration evoked a prolonged cold hy-
persensitivity, which was also delayed in its onset (Figure 3).
Signicant cold hypersensitivity was evident on day 14, peaked
on day 28, and then persisted until day 90 following paclitaxel
initiation (Figure 3; n  12 per group; p< 0.05, the Friedman
test with Dunn’s post hoc test comparing baseline scores).
Following three consecutive nonsignicant data points, the
cold hypersensitivity was deemed to have resolved on day 132
(Figure 3). Heat hypersensitivity was assessed until day 45
following paclitaxel initiation (Figure 4). We did not nd
evidence that paclitaxel evoked either early- or late-phase heat
hypersensitivity compared to concurrent vehicle-treated
controls (Figure 4; n  6 per group).
As shown in Figure 5, low-dose paclitaxel administration
did not signicantly a
ect motor coordination assessed via
latency to fall from an accelerating RotaRod apparatus.
Motor coordination was assessed until day 90 following
paclitaxel administration, and no change in latency was
observed compared to concurrent vehicle-treated control
animals (Figure 5; n  6 per group). e decrease in latency
observed in both paclitaxel- and vehicle-treated rats at later
time points of the time course is likely due to the increased
size of the rats.
Figure 6 shows the e
ect of low-dose paclitaxel ad-
ministration on spontaneous burrowing behaviour. On day
7, 24 hours after the last injection of paclitaxel, there was no
statistically signicant di
erence in the burrowing behaviour
of paclitaxel-treated rats compared to vehicle-treated rats.
However, on day 28 (the peak of mechanical and cold hy-
persensitivity), there was a signicant 39% reduction in the
total gravel burrowed by paclitaxel-treated rats compared to
their baseline responses (Figure 6(a); n  6 per group;
p< 0.05, one-way repeated measures ANOVA with Dun-
nett’s post hoc test). No signicant change in burrowing
behaviour was observed in the vehicle-treated rats. ere
was a tendency of paclitaxel-treated rats to take a longer time
to start burrowing on day 28 (Figure 6(b)), but this was not
statistically signicant.
Figure 7 shows the overnight (7.10 pm–6.20 am) spon-
taneous wheel-running behaviour of paclitaxel- and vehicle-
treated rats on days 7, 28, and 35 after treatment initiation.
On day 7, there was no signicant di
erence between
treatment groups on any of the parameters recorded. In
contrast, on day 28, paclitaxel-treated rats showed a signif-
icant decrease in the time spent on the wheel (Figure 7(a);
p  0.004) and total distance ran on the wheel (Figure 7(b);
p  0.004) compared to concurrent vehicle-treated rats
(n  9-10 per group; p< 0.05, two-way repeated measures
ANCOVA with Bonferroni pairwise analysis). On day 28,
decreases were also observed in maximal acceleration
(Figure 7(c); p  0.060) and the number of times they en-
tered the wheel (Figure 7(d); p  0.054); however, these
observations did not reach statistical signicance. On day 35,
paclitaxel-treated rats spent signicantly less time on the
wheel (Figure 7(a); p  0.038), with decreased total distance
ran overnight (Figure 7(b); p  0.050) compared to con-
current vehicle-treated rats (Figures 7(a) and 7(b); n  9-10
per group; p< 0.05, two-way repeated measures ANCOVA
with Bonferroni pairwise analysis). ere was no change in
the mean speed between treatment groups at any time point
investigated. Dusk-phase (6-7 pm) spontaneous wheel-
running behaviour was also signicantly impaired in
paclitaxel-treated rats, but only on day 28 with two mea-
sures. Paclitaxel-treated rats spent signicantly less time on
the wheel (a 27.6% decrease) and ran less (a 32.1% decrease)
during the dusk phase, compared to concurrent vehicle-
treated rats (data not shown). ese data suggest that
monitoring activity during the dark phase provides the
maximum information on impaired rat activity.
Further assessment of burrowing behaviour and spon-
taneous wheel running at later time points was not assessed
because larger rats are unable to t in the burrowing tubes and
wheels. In addition, our RotaRod data (Figure 5) suggest that
as they gained weight, they became less active. erefore, the
animals in these experiments were terminated after the time
points shown in Figures 6 and 7.
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Figure 1: Time course of weight gain in rats following paclitaxel or
vehicle administration. Graph shows mean± SEM of rats’ weight (g)
from before paclitaxel/vehicle administration (BL) up to day 174.
Arrows indicate four injections of 2mg/kg paclitaxel or equivalent
volume of vehicle on days 0, 2, 4, and 6 (n  18 per group).
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4. Discussion
In this study, we have shown the complete time course of
evoked pain-like behaviours following low-dose systemic
paclitaxel administration. Administration of 2mg/kg clini-
cally formulated paclitaxel on days 0, 2, 4, and 6 induced
a robust and persistent hind paw hypersensitivity to me-
chanical and cold stimuli. However, paclitaxel-treated rats
did not develop heat hypersensitivity nor did they show any
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Figure 2: Time course of paclitaxel-inducedmechanical hypersensitivity. Graphs show themean± SEMof the number of withdrawal responses
to (a) von Frey 4 g, (b) von Frey 8 g, and (c) von Frey 15 g, respectively. Arrows indicate four injections of 2mg/kg paclitaxel or equivalent
volume of vehicle on days 0, 2, 4, and 6. BL baseline before paclitaxel/vehicle administration. Res resolution of mechanical hypersensitivity,
which occurred between days 174 and 219. ∗p< 0.05, two-tailed unpaired t-tests with Bonferroni correction (n  15–21 per group).
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Figure 3: Time course of paclitaxel-induced cold hypersensitivity.
Graph shows the median± interquartile range of the hind paw
response to acetone application catergorised by the cold score.
BL baseline before paclitaxel/vehicle administration. Arrows in-
dicate four injections of 2mg/kg paclitaxel or equivalent volume of
vehicle on days 0, 2, 4, and 6. ∗p< 0.05, the Friedman test with
Dunn’s post hoc test comparing the baseline scores in each group
(n  12 per group). As this analysis is nonparametric, the error bars
appear larger than expected from parametric analysis.
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Figure 4: E
ect of paclitaxel administration on heat hypersensi-
tivity. Graph shows the mean± SEM of the hind paw withdrawal
latency to a radiant heat stimulus. BL baseline before paclitax-
el/vehicle administration. Arrows indicate four injections of
2mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4,
and 6 (n  6 per group).
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alterations in motor coordination. We also report, for the
rst time, evidence for ongoing pain-like behaviour in this
low-dose paclitaxel model using two ethologically relevant
behavioural tests. Paclitaxel-treated rats showed a reduction
in both burrowing behaviour and nocturnal spontaneous
wheel-running activity. Interestingly, we found that the time
courses of evoked and ongoing pain-like behaviours were
similar, with a delayed onset.
We consistently observed good overall health in
paclitaxel-treated rats across di
erent cohorts, with normal
weight gain and no signs of alopecia or diarrhoea. Mild
weight loss has been previously reported at this dosage [32],
and signicant weight loss has been observed with higher
paclitaxel dosing regimens [33, 34]. Paclitaxel did not im-
mediately evoke mechanical and cold hypersensitivity after
administration but rather was delayed in its onset until
a week after the last injection of paclitaxel. By day 14,
signicant mechanical/cold hypersensitivity was observed,
which then increased to a peak approximately one month
after the rst paclitaxel injection. Paclitaxel-induced me-
chanical and cold hypersensitivity then persisted for several
months. e decline of these behaviours di
ered, with cold
hypersensitivity being completely resolved approximately
50 days earlier thanmechanical hypersensitivity. Mechanical
and cold hypersensitivity has also been described in
paclitaxel-treated patients [3, 35].e delayed and persistent
hypersensitivity observed in this rat model is similar to the
coasting phenomenon and persistence of pain seen in the
clinic.
Rats in this investigation did not show any alteration
in heat sensitivity following paclitaxel administration,
compared to vehicle-treated controls, at any time point
investigated. A previous study has also reported an absence
of hind paw heat hypersensitivity following a cumulative dose
of 8mg/kg paclitaxel dissolved in 10% saline and Cremophor
vehicle [36]. Other rodent models also report an absence of
altered heat sensitivity following paclitaxel administration
[33, 37]. Patients who report paclitaxel-induced pain show
thermal hypoalgesia/increased heat detection thresholds
[3, 4, 38]. However, this is observed only in animal models
that use high cumulative doses of paclitaxel (25mg/kg [32];
32 and 80mg/kg [34]; and 64.8mg/kg [39]). It is possible that
the marked neurodegeneration associated with high doses of
paclitaxel may underlie the change in heat perception seen by
others. is contrasts with the lack of change in heat per-
ception seen in this model, which corresponds to an absence
of marked neurodegeneration following the 8mg/kg dosing
regimen [40].
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Figure 5: E
ect of paclitaxel administration on motor co-
ordination. Graph shows themean± SEM of the latency to fall from
an accelerating RotaRod apparatus. BL baseline before paclitax-
el/vehicle administration. Arrows indicate four injections of
2mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4,
and 6 (n  6 per group).
BL 7 28
0
500
1000
1500
2000
2500
G
ra
ve
l b
ur
ro
w
ed
 (g
)
Days aer initial injection
∗
Vehicle
Paclitaxel
(a)
Days aer initial injection
Vehicle
Paclitaxel
BL 7 28
0
500
1000
1500
La
te
nc
y 
to
 b
ur
ro
w
 (s
)
(b)
Figure 6: E
ect of paclitaxel administration on spontaneous
burrowing behaviour. Graphs show the mean± SEM of (a) gravel
displaced from burrowing tubes and (b) latency to start burrowing
by individual rats before paclitaxel/vehicle administration (BL) and
then on day 7 and day 28 following the initial injection of 2mg/kg
paclitaxel or vehicle. ∗p< 0.05, one-way repeated measures
ANOVA with Dunnett’s post hoc test comparing the baseline
burrowing capacity (n  6 per group).
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Motor symptoms are not commonly reported in patients
receiving paclitaxel, unless they received high cumulative
doses which evoked mild, distal weakness [3, 4, 41, 42]. We
found that motor coordination was unaltered at any time
point following paclitaxel administration. ese ndings
conrm and temporally extend previous data showing that
motor coordination was una
ected up to 3 weeks following
similar or lower paclitaxel doses [36]. However, impairment
of motor coordination assessed by RotaRod has been re-
ported in rats following high cumulative doses of paclitaxel
(25mg/kg [32] and 36mg/kg [43]).
More recently, there has been an emphasis on the re-
quirement of better reporting of behavioural models and of
developing methods to report ongoing pain [44–46].
Ethologically relevant behavioural assessment is a valuable
methodology to implement as it measures normal rat
behaviour/activity and thus can be an indicator of ongoing
pain-like behaviour. In this study, we have shown that
both burrowing behaviour and nocturnal spontaneous
wheel running are impaired by low-dose paclitaxel ad-
ministration. Importantly, this study provides the rst
evidence for ongoing pain-like behaviour in a rat model of
paclitaxel-induced peripheral neuropathy. Burrowing be-
haviour was impaired on day 28 after paclitaxel initiation,
but not immediately following paclitaxel dosing on day 7.
Similarly, several measures of nocturnal spontaneous wheel
running were signicantly impeded in paclitaxel-treated rats
on days 28 and 35 after paclitaxel initiation, but were un-
a
ected on day 7, which is 24 hours after the last injection of
paclitaxel. erefore, the impairment of spontaneous
ethological behaviours temporally re¦ects the occurrence of
maximal evoked mechanical and cold hypersensitivity.
Alterations in burrowing behaviour have been reported
in several rodent pain models evoked by peripheral nerve
injury [15, 16, 47], hind paw in¦ammation [15, 16, 29], joint
in¦ammation [30, 48], and antiretroviral drug treatment
[28]. A recent investigation reported a standard burrowing
protocol across multiple centres showing a consistent decit
in burrowing behaviour following CFA-induced hind paw
in¦ammation [29]. is study also identied several vari-
ables which had a signicant impact on sensitivity, including
the number of training sessions provided and animal weight
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Figure 7: E
ect of paclitaxel administration on overnight spontaneous wheel-running behaviour. Graphs show themean± SEMof the (a) time
spent on the wheel, (b) total distance travelled, (c) maximal acceleration generated, and (d) number of times the wheel was accessed by
individual rats overnight (7.10 pm–6.30 am) before paclitaxel/vehicle administration (BL) and then on day 7, day 28, and day 35 following the
initial injection of 2mg/kg paclitaxel or vehicle. Arrows indicate four injections of 2mg/kg paclitaxel or equivalent volume of vehicle on days 0,
2, 4, and 6. ∗p< 0.05, two-way repeated measures ANCOVA with Bonferroni pairwise analysis (n  10 vehicle rats and n  9 paclitaxel rats).
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at the time of injury. Collectively, these studies suggest that
burrowing can identify ongoing pain-like behaviour in
several diﬀerent pain models and may be confounded by
several of the same factors which produce variability in
evoked-pain testing.
Nocturnal spontaneous wheel running is perhaps a more
novel behavioural assessment in research but reﬂects an-
other ethological elective behaviour in rodents [17]. -e
ability to monitor this behaviour without the need for an
experimenter to be present enables the possibility of long-
term nocturnal assessment, as we report here. Spontaneous
wheel running has not yet been used as widely as burrowing
in preclinical pain studies. However, impairment of spon-
taneous wheel-running measures has been reported fol-
lowing hind paw inﬂammation in rats [19] andmice [18] and
in a mouse model of osteoarthritis [49]. In our study, on day
28, we found that more measures (time spent on wheel, total
distance ran, maximal acceleration, and wheel entries) of
spontaneous wheel running were impaired during assess-
ment overnight (7.10 pm–6.20 am) compared to assessment
during the dusk phase (6-7 pm) only. -is indicates an
advantage to nocturnal assessment of this behaviour, when
rats are most active [31].
It is unlikely that the impairment of spontaneous
ethological behaviours by paclitaxel reported here is due to
a deﬁcit in motor function because paclitaxel-treated rats
performed similarly to vehicle-treated rats on an accelerated
RotaRod apparatus throughout the time course. We suggest
that this reduction in spontaneous wheel-running and
burrowing performance emulates the ongoing nature of pain
reported by patients treated with paclitaxel. Furthermore, as
there was no signiﬁcant impairment of these spontaneous
ethological behaviours on day 7, 24 hours after the last
injection of paclitaxel, these behaviours are not a measure of
acute drug toxicity.
5. Conclusions
Low-dose intermittent administration of paclitaxel induces
long-lasting mechanical and cold hypersensitivity, without
deﬁcits in heat sensation and motor coordination. Pacli-
taxel also induces ongoing pain-like behaviour shown
through the impairment of innate burrowing and wheel-
running behaviours, which occurs in parallel with the peak
of evoked pain-like behaviours. -is study improves the
face validity of this rat model of paclitaxel-induced pe-
ripheral neuropathy by detailing the measurable evoked
and ongoing pain-like behaviours evoked by clinically
formulated paclitaxel. -e assessment of both evoked and
ongoing pain-like behaviours may aid the translation of
novel treatments to alleviate paclitaxel-induced neuro-
pathic pain in the clinic.
Data Availability
-e data underlying this study are not suitable for data
mining. However, the data are available from the corre-
sponding author upon request or at the following lab’s
website: www.kcl.ac.uk/ﬂatterslab.
Conflicts of Interest
-e authors have no conﬂicts of interest to declare with this
work or its submission for publication.
Acknowledgments
-e authors thank Clive Gentry for his help and advice in
setting up the RotaRod experiments and Andrew Rice for his
advice on burrowing experiments and loan of equipment.
-e authors are grateful for their time shared with the late,
great, Ann L. Pitcher and her excellent contribution to the
Sarah Flatters Lab and teaching activities. -is study was
funded by the Capacity Building Award in Integrative
Mammalian Biology provided by a consortium of funders:
Biotechnology and Biological Sciences Research Council;
British Pharmacological Society Integrative Pharmacology
Fund; Higher Education Funding Council for England;
Department for Innovation, Universities and Skills; Medical
Research Council; and Scottish Funding Council. -is
study was also supported by -e Wellcome Trust
(WT093335AIA).
References
[1] C. Tofthagen, R. D. McAllister, and C. Visovsky, “Peripheral
neuropathy caused by paclitaxel and docetaxel: an evaluation
and comparison of symptoms,” Journal of the Advanced
Practitioner in Oncology, vol. 4, no. 4, pp. 204–215, 2013.
[2] S. J. L. Flatters, P. M. Dougherty, and L. A. Colvin, “Clinical
and preclinical perspectives on chemotherapy-induced pe-
ripheral neuropathy (CIPN): a narrative review,” British
Journal of Anaesthesia, vol. 119, no. 4, pp. 737–749, 2017.
[3] C. Augusto, M. Pietro, M. Cinzia et al., “Peripheral neu-
ropathy due to paclitaxel: study of the temporal relationships
between the therapeutic schedule and the clinical quantitative
score (QST) and comparison with neurophysiological ﬁnd-
ings,” Journal of Neuro-Oncology, vol. 86, no. 1, pp. 89–99,
2008.
[4] J. A. Boyette-Davis, J. P. Cata, L. C. Driver et al., “Persistent
chemoneuropathy in patients receiving the plant alkaloids
paclitaxel and vincristine,” Cancer Chemotherapy and Phar-
macology, vol. 71, no. 3, pp. 619–626, 2013.
[5] P. A. Forsyth, C. Balmaceda, K. Peterson, A. D. Seidman,
P. Brasher, and L. M. DeAngelis, “Prospective study of
paclitaxel-induced peripheral neuropathy with quantitative
sensory testing,” Journal of Neuro-Oncology, vol. 35, no. 1,
pp. 47–53, 1997.
[6] M. J. van den Bent, V. J. van Raaij-van den Aarssen, J. Verweij,
P. A. Doorn, and P. A. Sillevis Smitt, “Progression of
paclitaxel-induced neuropathy following discontinuation of
treatment,” Muscle and Nerve, vol. 20, no. 6, pp. 750–752,
1997.
[7] T. J. Postma, J. B. Vermorken, A. J. Liefting, H.M. Pinedo, and
J. J. Heimans, “Paclitaxel-induced neuropathy,” Annals of
Oncology, vol. 6, no. 5, pp. 489–494, 1995.
[8] M. Seretny, G. L. Currie, E. S. Sena et al., “Incidence, prev-
alence, and predictors of chemotherapy-induced peripheral
neuropathy: a systematic review and meta-analysis,” Pain,
vol. 155, no. 12, pp. 2461–2470, 2014.
[9] D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., “Pre-
vention and management of chemotherapy-induced
Pain Research and Management 9
peripheral neuropathy in survivors of adult cancers: American
Society of Clinical Oncology clinical practice guideline,”
Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941–1967,
2014.
[10] N. Majithia, S. M. Temkin, K. J. Ruddy, A. S. Beutler,
D. L. Hershman, and C. L. Loprinzi, “National Cancer
Institute-supported chemotherapy-induced peripheral neu-
ropathy trials: outcomes and lessons,” Supportive Care in
Cancer, vol. 24, no. 3, pp. 1439–1447, 2016.
[11] E. Smith, H. Pang, C. Cirrincione et al., “Eﬀect of duloxetine
on pain, function, and quality of life among patients with
chemotherapy-induced painful peripheral neuropathy:
a randomized clinical trial,” JAMA, vol. 309, no. 13,
pp. 1359–1367, 2013.
[12] H. L. Hopkins, N. A. Duggett, and S. J. Flatters,
“Chemotherapy-induced painful neuropathy: pain-like be-
haviours in rodent models and their response to commonly
used analgesics,” Current Opinion in Supportive and Palliative
Care, vol. 10, no. 2, pp. 119–128, 2016.
[13] R. M. Deacon, “Burrowing in rodents: a sensitive method for
detecting behavioral dysfunction,” Nature Protocols, vol. 1,
no. 1, pp. 118–121, 2006.
[14] N. Andrews, S. Harper, Y. Issop, and A. S. Rice, “Novel,
nonreﬂex tests detect analgesic action in rodents at clinically
relevant concentrations,” Annals of the New York Academy of
Sciences, vol. 1245, no. 1, pp. 11–13, 2011.
[15] N. Andrews, E. Legg, D. Lisak et al., “Spontaneous burrowing
behaviour in the rat is reduced by peripheral nerve injury or
inﬂammation associated pain,” European Journal of Pain,
vol. 16, no. 4, pp. 485–495, 2012.
[16] A. Muralidharan, A. Kuo, M. Jacob et al., “Comparison of
burrowing and stimuli-evoked pain behaviors as end-points
in rat models of inﬂammatory pain and peripheral neuro-
pathic pain,” Frontiers in Behavioral Neuroscience, vol. 10,
p. 88, 2016.
[17] J. H. Meijer and Y. Robbers, “Wheel running in the wild,”
Proceedings of the Royal Society B: Biological Sciences, vol. 281,
no. 1786, p. 20140210, 2014.
[18] E. J. Cobos, N. Ghasemlou, D. Araldi, D. Segal, K. Duong, and
C. J. Woolf, “Inﬂammation-induced decrease in voluntary
wheel running in mice: a nonreﬂexive test for evaluating
inﬂammatory pain and analgesia,” Pain, vol. 153, no. 4,
pp. 876–884, 2012.
[19] R. Kandasamy, J. J. Calsbeek, and M. M. Morgan, “Home
cage wheel running is an objective and clinically relevant
method to assess inﬂammatory pain in male and female
rats,” Journal of Neuroscience Methods, vol. 263, pp. 115–122,
2016.
[20] L. A. Griﬃths and S. J. L. Flatters, “Pharmacological modu-
lation of the mitochondrial electron transport chain in
paclitaxel-induced painful peripheral neuropathy,” Journal of
Pain, vol. 16, no. 10, pp. 981–994, 2015.
[21] N. A. Duggett, L. A. Griﬃths, O. E. McKenna et al., “Oxidative
stress in the development, maintenance and resolution of
paclitaxel-induced painful neuropathy,” Neuroscience,
vol. 333, pp. 13–26, 2016.
[22] N. A. Duggett, L. A. Griﬃths, and S. J. L. Flatters, “Paclitaxel-
induced painful neuropathy is associated with changes in
mitochondrial bioenergetics, glycolysis, and an energy deﬁcit
in dorsal root ganglia neurons,” Pain, vol. 158, no. 8,
pp. 1499–1508, 2017.
[23] M. Zimmermann, “Ethical guidelines for investigations of
experimental pain in conscious animals,” Pain, vol. 16, no. 2,
pp. 109-110, 1983.
[24] M. Fidanboylu, L. A. Griﬃths, and S. J. L. Flatters, “Global
inhibition of reactive oxygen species (ROS) inhibits paclitaxel-
induced painful peripheral neuropathy,” PLoS One, vol. 6,
no. 9, article e25212, 2011.
[25] S. J. L. Flatters and G. J. Bennett, “Ethosuximide reverses
paclitaxel- and vincristine-induced painful peripheral neu-
ropathy,” Pain, vol. 109, no. 1-2, pp. 150–161, 2004.
[26] K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A
new and sensitive method for measuring thermal nociception
in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88,
1988.
[27] N. W. Dunham and T. S. Miya, “A note on a simple apparatus
for detecting neurological deﬁcit in rats and mice,” Journal of
the American Pharmaceutical Association, vol. 46, no. 3,
pp. 208-209, 1957.
[28] W. Huang, M. Calvo, K. Karu et al., “A clinically relevant
rodent model of the HIV antiretroviral drug stavudine in-
duced painful peripheral neuropathy,” Pain, vol. 154, no. 4,
pp. 560–575, 2013.
[29] R. Wodarski, A. Delaney, C. Ultenius et al., “Cross-centre
replication of suppressed burrowing behaviour as an etho-
logically relevant pain outcome measure in the rat,” Pain,
vol. 157, no. 10, pp. 2350–2365, 2016.
[30] K. Rutten, K. Schiene, A. Robens et al., “Burrowing as a non-
reﬂex behavioural readout for analgesic action in a rat model
of sub-chronic knee joint inﬂammation,” European Journal of
Pain, vol. 18, no. 2, pp. 204–212, 2014.
[31] R. Eikelboom and R. Mills, “A microanalysis of wheel running
in male and female rats,” Physiology and Behavior, vol. 43,
no. 5, pp. 625–630, 1988.
[32] G. Cavaletti, E. Cavalletti, P. Montaguti, N. Oggioni, O. De
Negri, and G. Tredici, “Eﬀect on the peripheral nervous
system of the short-term intravenous administration of
paclitaxel in the rat,” Neurotoxicology, vol. 18, no. 1,
pp. 137–145, 1997.
[33] K. D. Cliﬀer, J. A. Siuciak, S. R. Carson et al., “Physiological
characterization of Taxol-induced large-ﬁber sensory neu-
ropathy in the rat,” Annals of Neurology, vol. 43, no. 1,
pp. 46–55, 1998.
[34] N. Authier, J. P. Gillet, J. Fialip, A. Eschalier, and F. Coudore,
“Description of a short-term Taxol-induced nociceptive
neuropathy in rats,” Brain Research, vol. 887, no. 2,
pp. 239–249, 2000.
[35] P. M. Dougherty, J. P. Cata, J. V. Cordella, A. Burton, and
H. R. Weng, “Taxol-induced sensory disturbance is charac-
terized by preferential impairment of myelinated ﬁber
function in cancer patients,” Pain, vol. 109, no. 1-2,
pp. 132–142, 2004.
[36] R. C. Polomano, A. J. Mannes, U. S. Clark, and G. J. Bennett,
“A painful peripheral neuropathy in the rat produced by the
chemotherapeutic drug, paclitaxel,” Pain, vol. 94, no. 3,
pp. 293–304, 2001.
[37] S. B. Smith, S. E. Crager, and J. S. Mogil, “Paclitaxel-induced
neuropathic hypersensitivity in mice: responses in 10 inbred
mouse strains,” Life Sciences, vol. 74, no. 21, pp. 2593–2604,
2004.
[38] S. B. Park, C. S. Lin, A. V. Krishnan, M. L. Friedlander,
C. R. Lewis, and M. C. Kiernan, “Early, progressive, and
sustained dysfunction of sensory axons underlies paclitaxel-
induced neuropathy,” Muscle and Nerve, vol. 43, no. 3,
pp. 367–374, 2011.
[39] S. C. Apfel, R. B. Lipton, J. C. Arezzo, and J. A. Kessler, “Nerve
growth factor prevents toxic neuropathy in mice,” Annals of
Neurology, vol. 29, no. 1, pp. 87–90, 1991.
10 Pain Research and Management
[40] S. J. L. Flatters and G. J. Bennett, “Studies of peripheral
sensory nerves in paclitaxel-induced painful peripheral
neuropathy: evidence for mitochondrial dysfunction,” Pain,
vol. 122, no. 3, pp. 245–257, 2006.
[41] P. H. Wiernik, E. L. Schwartz, A. Einzig, J. J. Strauman,
R. B. Lipton, and J. P. Dutcher, “Phase I trial of Taxol given as
a 24-hour infusion every 21 days: responses observed in
metastatic melanoma,” Journal of Clinical Oncology, vol. 5,
no. 8, pp. 1232–1239, 1987.
[42] R. J. Freilich, C. Balmaceda, A. D. Seidman, M. Rubin, and
L. M. DeAngelis, “Motor neuropathy due to docetaxel and
paclitaxel,” Neurology, vol. 47, no. 1, pp. 115–118, 1996.
[43] F. M. Boyle, H. R. Wheeler, and G. M. Shenﬁeld, “Amelio-
ration of experimental cisplatin and paclitaxel neuropathy
with glutamate,” Journal of Neuro-Oncology, vol. 41, no. 2,
pp. 107–116, 1999.
[44] A. S. Rice, D. Cimino-Brown, J. C. Eisenach et al., “Animal
models and the prediction of eﬃcacy in clinical trials of
analgesic drugs: a critical appraisal and call for uniform
reporting standards,” Pain, vol. 139, no. 2, pp. 243–247, 2008.
[45] J. S. Mogil and S. E. Crager, “What should we be measuring in
behavioral studies of chronic pain in animals?,” Pain, vol. 112,
no. 1-2, pp. 12–15, 2004.
[46] J. S. Mogil, K. D. Davis, and S. W. Derbyshire, “-e necessity
of animal models in pain research,” Pain, vol. 151, no. 1,
pp. 12–17, 2010.
[47] W. Lau, C. Dykstra, S.-evarkunnel et al., “A back translation
of pregabalin and carbamazepine against evoked and non-
evoked endpoints in the rat spared nerve injury model of
neuropathic pain,” Neuropharmacology, vol. 73, pp. 204–215,
2013.
[48] L. A. Bryden, J. R. Nicholson, H. Doods, and A. Pekcec,
“Deﬁcits in spontaneous burrowing behavior in the rat bi-
lateral monosodium iodoacetate model of osteoarthritis: an
objective measure of pain-related behavior and analgesic
eﬃcacy,” Osteoarthritis and Cartilage, vol. 23, no. 9,
pp. 1605–1612, 2015.
[49] G. W. Stevenson, H. Mercer, J. Cormier et al., “Monosodium
iodoacetate-induced osteoarthritis produces pain-depressed
wheel running in rats: implications for preclinical behavioral
assessment of chronic pain,” Pharmacology Biochemistry and
Behavior, vol. 98, no. 1, pp. 35–42, 2011.
Pain Research and Management 11
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
